Literature DB >> 17062864

Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies.

Priti R Patel1, A Kirsten Larson, Amanda D Castel, Lilia M Ganova-Raeva, Robert A Myers, Brenda J Roup, Katherine P Farrell, Leslie Edwards, Omana Nainan, John P Krick, David Blythe, Anthony E Fiore, Jeffrey C Roche.   

Abstract

CONTEXT: Nuclear pharmacies prepare radiopharmaceutical products for use in common diagnostic procedures, including myocardial perfusion studies. Hepatitis C virus (HCV) transmission has not been reported previously in the setting of nuclear imaging studies.
OBJECTIVE: To investigate an outbreak of acute HCV infection identified among patients who underwent myocardial perfusion studies on October 15, 2004, using an injected radiopharmaceutical. DESIGN, SETTING, AND PATIENTS: Outbreak investigation including molecular epidemiology and pharmacy site investigation at outpatient cardiology clinics and a nuclear pharmacy in Maryland. Ninety patients who received injections drawn from select radiopharmaceutical vials prepared on October 14-15, 2004, at a single nuclear pharmacy were offered testing for bloodborne pathogens. Pharmacy procedures were reviewed and HCV quasi species analysis was performed. MAIN OUTCOME MEASURES: Hepatitis C virus infection and quasispecies sequence similarity.
RESULTS: Sixteen patients with acute HCV infection were identified from 3 separate clinics. All patients received radiopharmaceutical injections drawn from a single pharmacy vial (vial 1). None of the 59 tested patients who received doses from 6 other vials had acute HCV infection. Blood from a potential source patient with HCV and human immunodeficiency virus (HIV) infection was processed for a radiolabeled white blood cell study in the pharmacy 12 hours before vial 1 was prepared. The HCV quasispecies sequences from this potential source patient were nearly identical to those from cases (97.8%-98.5% similarity). No acute HIV infections were identified. Pharmacy practices that could have led to blood cross-contamination included reuse of needles and syringes during dilutions and use of common flow hoods for some steps in the preparation of sterile and blood-derived products.
CONCLUSIONS: Sixteen persons acquired HCV infection from a blood-contaminated radiopharmaceutical. The source and practices that could have facilitated breaks in aseptic technique were identified at the pharmacy. Nuclear pharmacies that handle biological products should follow appropriate aseptic technique to prevent contamination of sterile radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17062864     DOI: 10.1001/jama.296.16.2005

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

Review 1.  U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned.

Authors:  Nadine Shehab; Megan N Brown; Alexander J Kallen; Joseph F Perz
Journal:  J Patient Saf       Date:  2018-09       Impact factor: 2.844

Review 2.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

Review 3.  Estimating acute viral hepatitis infections from nationally reported cases.

Authors:  R Monina Klevens; Stephen Liu; Henry Roberts; Ruth B Jiles; Scott D Holmberg
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

4.  The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection.

Authors:  K England; C Thorne; H Harris; M Ramsay; M-L Newell
Journal:  J Viral Hepat       Date:  2011-06-22       Impact factor: 3.728

5.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

6.  Outbreak of hepatitis B and hepatitis C virus infections associated with a cardiology clinic, West Virginia, 2012-2014.

Authors:  Stacy R Tressler; Maria C Del Rosario; Michelle D Kirby; Ashley N Simmons; Melissa A Scott; Sherif Ibrahim; Joseph C Forbi; Hong Thai; Guo-Liang Xia; Meghan Lyman; Melissa G Collier; Priti R Patel; Danae Bixler
Journal:  Infect Control Hosp Epidemiol       Date:  2021-03-01       Impact factor: 6.520

7.  Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl.

Authors:  Lisa L Maragakis; Romanee Chaiwarith; Arjun Srinivasan; Francesca J Torriani; Edina Avdic; Andrew Lee; Tracy R Ross; Karen C Carroll; Trish M Perl
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

Review 8.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.